PMID: identifiant
de la référence Pubmed : |
 |
 (22252372)  |
|
| titre : |
|
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. |
|
| auteur(s) : |
|
Vincent Camus ( ) 1, Pierre Payoux2, Louisa Barré3, Béatrice Desgranges4, Thierry Voisin5, Clovis Tauber1, Renaud La Joie4, Mathieu Tafani2, Caroline Hommet1, Gaël Chételat4, Karl Mondon1, Vincent De La Sayette4, Jean-Philippe Cottier1, Emilie Beaufils1, Maria-Joao Ribeiro1, Valérie Gissot6, Emilie Vierron1, Johnny Vercouillie1, D. Skovronsky7, Bruno Vellas5, Francis Eustache4, Denis GUILLOTEAU1, 6 |
|
| laboratoire : |
|
|
|
| résumé : |
|
PURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has been suggested as a core biomarker for Alzheimer's disease (AD). The aim of this study was to test the feasibility of using PET imaging with (18)F-AV-45 (florbetapir) in a routine clinical environment to differentiate between patients with mild to moderate AD and mild cognitive impairment (MCI) from normal healthy controls (HC). METHODS: In this study, 46 subjects (20 men and 26 women, mean age of 69.0 ± 7.6 years), including 13 with AD, 12 with MCI and 21 HC subjects, were enrolled from three academic memory clinics. PET images were acquired over a 10-min period 50 min after injection of florbetapir (mean ± SD of radioactivity injected, 259 ± 57 MBq). PET images were assessed visually by two individuals blinded to any clinical information and quantitatively via the standard uptake value ratio (SUVr) in the specific regions of interest, which were defined in relation to the cerebellum as the reference region. RESULTS: The mean values of SUVr were higher in AD patients (median 1.20, Q1-Q3 1.16-1.30) than in HC subjects (median 1.05, Q1-Q3 1.04-1.08; p = 0.0001) in the overall cortex and all cortical regions (precuneus, anterior and posterior cingulate, and frontal median, temporal, parietal and occipital cortex). The MCI subjects also showed a higher uptake of florbetapir in the posterior cingulate cortex (median 1.06, Q1-Q3 0.97-1.28) compared with HC subjects (median 0.95, Q1-Q3 0.82-1.02; p = 0.03). Qualitative visual assessment of the PET scans showed a sensitivity of 84.6% (95% CI 0.55-0.98) and a specificity of 38.1% (95% CI 0.18-0.62) for discriminating AD patients from HC subjects; however, the quantitative assessment of the global cortex SUVr showed a sensitivity of 92.3% and specificity of 90.5% with a cut-off value of 1.122 (area under the curve 0.894). CONCLUSION: These preliminary results suggest that PET with florbetapir is a safe and suitable biomarker for AD that can be used routinely in a clinical environment. However, the low specificity of the visual PET scan assessment could be improved by the use of specific training and automatic or semiautomatic quantification tools. |
|
| domaine : |
|
Sciences du Vivant/Neurosciences
|
|
langue du texte
intégral : |
|
Anglais |
|
| ISSN : |
|
1619-7089 |
|
|
| type de publication : |
|
Articles dans des revues avec comité de lecture |
|
| DOI : |
|
10.1007/s00259-011-2021-8 |
|
| journal : |
|
| European Journal of Nuclear Medicine and Molecular Imaging (Eur J Nucl Med Mol Imaging) |
| Publisher |
Springer Verlag (Germany) |
| ISSN |
1619-7070 (eISSN : 1619-7089) |
|
|
| Audience : |
|
internationale |
|
| date de publication : |
|
04/2012 |
|
date de publication
électronique : |
|
18/01/2012 |
|
| volume : |
|
39 |
|
| numéro : |
|
4 |
|
| page, identifiant, ... : |
|
621-31 |
|
|
| Descripteur(s) MeSH : |
|
Aged – Alzheimer Disease – Amyloid – Aniline Compounds – Brain – Ethylene Glycols – Female – Follow-Up Studies – Humans – Male – Mild Cognitive Impairment – Positron-Emission Tomography |
|
| contrat, financement : |
|
This work was funded by the French Ministry of Heath with grant N° PHRC-N 2008-1004 and in part by the EC-FP6-project DiMI, LSHB-CT-2005-512146, the Région Centre and FEDER: "Radex" programs. This work was conducted with the support of the GIS Radiopharmaceutiques Caen, Toulouse, and Tours centres. |
|
